Metastatic Prostate Carcinoma Evidence of
Item
must have evidence of confirmed metastatic prostate cancer
boolean
C0936223 (UMLS CUI [1,1])
C0332120 (UMLS CUI [1,2])
Serum testosterone measurement
Item
serum testosterone must be less than 50 ng/ml
boolean
C0428413 (UMLS CUI [1])
Antiandrogen therapy | Disease Progression
Item
disease must be progressing despite anti-androgen therapy
boolean
C0279492 (UMLS CUI [1])
C0242656 (UMLS CUI [2])
Raised prostate specific antigen
Item
psa level must be elevated
boolean
C0178415 (UMLS CUI [1])
Inclusion Criteria Additional
Item
additional criteria determined at screening visit
boolean
C1512693 (UMLS CUI [1,1])
C1524062 (UMLS CUI [1,2])
Cytotoxic Chemotherapy Prostate carcinoma
Item
any previous cytotoxic chemotherapy for prostate cancer
boolean
C0677881 (UMLS CUI [1,1])
C0600139 (UMLS CUI [1,2])
Investigational New Drugs
Item
use of any investigational drug in the last 4 weeks
boolean
C0013230 (UMLS CUI [1])
Brain Neoplasms Symptomatic | Radiotherapy to brain Patient need for
Item
symptomatic brain tumors requiring radiation to the brain
boolean
C0006118 (UMLS CUI [1,1])
C0231220 (UMLS CUI [1,2])
C0948319 (UMLS CUI [2,1])
C0686904 (UMLS CUI [2,2])
Communicable Disease
Item
active infection
boolean
C0009450 (UMLS CUI [1])
Exclusion Criteria Additional
Item
additional criteria determined at screening visit
boolean
C0680251 (UMLS CUI [1,1])
C1524062 (UMLS CUI [1,2])